Stock ELDN ELEDON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Eledon Pharmaceuticals, Inc.

Equities

ELDN

US28617K1016

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/04/2024 am IST 		5-day change 1st Jan Change
2.06 USD +1.98% Intraday chart for Eledon Pharmaceuticals, Inc. +10.75% +14.44%
28/03 Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
25/03 Eledon Pharmaceuticals Says 12th Participant Enrolled in Tegoprubart Trial; Shares Rise After Hours MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
GL
Eledon Pharmaceuticals Says 12th Participant Enrolled in Tegoprubart Trial; Shares Rise After Hours
MT
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
GL
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
CI
Sector Update: Health Care Stocks Higher in Late Afternoon Trading
MT
Sector Update: Health Care
MT
Eledon Pharmaceuticals Says Tegoprubart Used in Kidney Transplant From Pig to Human
MT
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
GL
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
AQ
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
GL
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
GL
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
GL
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
GL
Transcript : Eledon Pharmaceuticals, Inc. - Special Call
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ELDN Stock
  4. News Eledon Pharmaceuticals, Inc.